The effect of MAPK inhibitors on arsenic trioxide-treated calu-6 lung cells in relation to cell death, ROS and GSH levels

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3837-3844

  Han, Yong Hwan ^a   Moon, Hwa Jin ^a   You, Bo Ra ^a   Kim, Sung Zoo ^a   Kim, Suhn Hee ^a   Park, Woo Hyun ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; Calu 6; GSH; MAPK; ROS

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARSENIC TRIOXIDE; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUPEROXIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN CALU 6; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; GLUTATHIONE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES;

EID: 71949097116     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Gonzalez C, Sanz-Alfayate G, Agapito MT, Gomez-Nino A, Rocher A and Obeso A: Significance of ROS in oxygen sensing in cell systems with sensitivity to physiological hypoxia. Respir Physiol Neurobiol 132: 17-41, 2002. (Pubitemid 34765687)
2. Baran CP, Zeigler MM, Tridandapani S and Marsh CB: The role of ROS and RNS in regulating life and death of blood monocytes. Curr Pharm Des 10: 855-866, 2004. (Pubitemid 38380064)
3. Zorov DB, Juhaszova M and Sollott SJ: Mitochondrial ROS-induced ROS release: An update and review. Biochim Biophys Acta 1757: 509-517, 2006.
4. Wilcox CS: Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4: 160-166, 2002.
5. Poot M, Teubert H, Rabinovitch PS and Kavanagh TJ: De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J Cell Physiol 163: 555-560, 1995.
6. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG and Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer 89: 1440-1447, 2000. (Pubitemid 30727208)
7. Lauterburg BH: Analgesics and glutathione. Am J Ther 9: 225-233, 2002.
8. Dasmahapatra G, Rahmani M, Dent P and Grant S: The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 107: 232-240, 2006. (Pubitemid 43053548)
9. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A and Breuer R: Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J Physiol Lung Cell Mol Physiol 290: L790-L796, 2006. (Pubitemid 43725085)
10. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998. (Pubitemid 28509343)
11. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK and Lee YY: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60: 3065-3071, 2000.
12. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A and Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12: 1383-1391, 1998. (Pubitemid 28442384)
13. Park WH, Cho YH, Jung CW, Park JO, Kim KY, Im YH, Lee MH, Kang WK and Park KC: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300: 230-235, 2003. (Pubitemid 36042957)
14. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK and Lee YY: Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 265: 400-404, 1999.
15. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K and Arima T: Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183: 147-153, 2002. (Pubitemid 34628418)
16. Li M, Cai JF and Chiu JF: Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 87: 29-38, 2002. (Pubitemid 34969145)
17. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999. (Pubitemid 29359187)
18. Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
19. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997. (Pubitemid 27097312)
20. Wu XX, Ogawa O and Kakehi Y: Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 24: 1489-1497, 2004.
21. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277, 1999. (Pubitemid 29019412)
22. Genestra M: Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal 19: 1807-1819, 2007.
23. Blenis J: Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 90: 5889-5892, 1993. (Pubitemid 23191418)
24. + exchange and ERK1/2. Circ Res 83: 824-831, 1998. (Pubitemid 28489079)
25. Hsin YH, Chen CF, Huang S, Shih TS, Lai PS and Chueh PJ: The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett 179: 130-139, 2008.
26. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, Fernandez-Gomez FJ, Concannon CG, Segura MF, Comella JX, Prehn JH and Jordan J: Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 71: 736-743, 2007. (Pubitemid 46294084)
27. 2. Role in cell survival following oxidant injury. J Biol Chem 271: 4138-4142, 1996. (Pubitemid 26070512)
28. Rygiel TP, Mertens AE, Strumane K, van der Kammen R and Collard JG: The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. J Cell Sci 121: 1183-1192, 2008. (Pubitemid 351753502)
29. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V and Bonati A: Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112: 2450-2462, 2008.
30. Ramos AM, Fernandez C, Amran D, Esteban D, de Blas E, Palacios MA and Aller P: Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J Cell Physiol 209: 1006-1015, 2006. (Pubitemid 44665723)
31. Potin S, Bertoglio J and Breard J: Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Lett 581: 118-124, 2007.
32. Kang YH and Lee SJ: The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 217: 23-33, 2008.
33. Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ and Chang CC: P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140: 169-180, 2008. (Pubitemid 350265041)
34. 2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett 270: 40-55, 2008.
35. Han YH, Kim SH, Kim SZ and Park WH: Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. J Cell Biochem 104: 862-878, 2008. (Pubitemid 351830836)
36. Han YH, Kim SZ, Kim SH and Park WH: Apoptosis in pyrogallol-treated Calu-6 cells is correlated with the changes of intracellular GSH levels rather than ROS levels. Lung Cancer 59: 301-314, 2008. (Pubitemid 351343831)
37. Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am J Physiol Renal Physiol 293: F511-520, 2007.
38. Han YH, Kim SH, Kim SZ and Park WH: Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer Calu-6 cells via the prevention of GSH depletion. Int J Oncol 33: 1099-1105, 2008.
39. Han YH, Kim SH, Kim SZ and Park WH: Intracellular GSH levels rather than ROS levels are tightly related to AMA-induced HeLa cell death. Chem Biol Interact 171: 67-78, 2008.
40. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA and Dang CV: Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 101: 4578-4583, 2004. (Pubitemid 38437453)
41. Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, Cho CK, Park IC, Park MJ, Rhee CH, Hong SI, Chung HY, Ue YS and Lee SJ: Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64: 8960-8967, 2004. (Pubitemid 39665504)
42. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999. (Pubitemid 29430427)
43. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q, Qian JQ and Xiang JZ: Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 27: 1078-1084, 2006. (Pubitemid 44127919)
44. 3)-induced apoptosis in human glioblastoma cells. Cancer Sci 96: 825-833, 2005. (Pubitemid 43019834)
45. Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG and Bonati A: Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 19: 234-244, 2005. (Pubitemid 40220588)
46. Kang YH and Lee SJ: Role of p38, MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol Rep 20: 637-643, 2008.
47. Shen ZY, Shen WY, Chen MH, Shen J and Zeng Y: Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As2O3. Int J Mol Med 11: 479-484, 2003.
48. Han YH, Kim SZ, Kim SH and Park WH: Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine. Int J Oncol 33: 205-213, 2008.
49. Han YH, Kim SZ, Kim SH and Park WH: Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. Mol Cells 26: 18-25, 2008.
50. Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH and Park S: Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94: 695-707, 2005. (Pubitemid 41420269)